Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported FCF Margin of 4.17% for Q1 2026, up 43511.0% on a YoY basis from N/an in Q1 2025, and down 67.39% quarter-over-quarter from 12.79% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported FCF Margin for 18 years, with the latest figure at 4.17% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 43511.0% year-over-year to 4.17%; the trailing twelve-month figure through Mar 2026 stood at 15.01% (up 1995.0% YoY), and the FY2025 full-year result was 12.53%, up 1443.0% from the prior year.
- FCF Margin for Q1 2026 stood at 4.17%, down from 12.79% in the prior quarter.
- The five-year high for FCF Margin was 45.61% in Q3 2023, with the low at 430.94% in Q1 2025.
- Historically, FCF Margin has averaged 38.34% across 5 years, with a median of 16.94% in 2024.
- Annual changes were most pronounced in 2025 — FCF Margin tumbled 41400 bps — and 2026, when it surged 43511 bps.
- Alnylam Pharmaceuticals' FCF Margin stood at 25.9% in 2022, then jumped by 60 bps to 10.26% in 2023, then sank by 71 bps to 17.49% in 2024, then jumped by 173 bps to 12.79% in 2025, then tumbled by 67 bps to 4.17% in 2026.
- The last three FCF Margin figures came in at 4.17% (Q1 2026), 12.79% (Q4 2025), and 23.52% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 4.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.17% |
| Dec 31, 2025 | 12.79% |
| Sep 30, 2025 | 23.52% |
| Jun 30, 2025 | 20.76% |
| Mar 31, 2025 | -430.94% |
| Dec 31, 2024 | -17.49% |
| Sep 30, 2024 | 3.91% |
| Jun 30, 2024 | 19.00% |
| Mar 31, 2024 | -16.94% |
| Dec 31, 2023 | -10.26% |
| Sep 30, 2023 | 45.61% |
| Jun 30, 2023 | -23.50% |
| Mar 31, 2023 | -56.49% |
| Dec 31, 2022 | -25.90% |
| Sep 30, 2022 | -49.86% |
| Jun 30, 2022 | -66.02% |
| Mar 31, 2022 | -84.18% |
| Dec 31, 2021 | -42.26% |
| Sep 30, 2021 | -85.33% |
| Jun 30, 2021 | -64.83% |